![Dollar rises on hawkish Fed talk; key inflation data looms](https://i-invdn-com.investing.com/news/LYNXMPEE0I024_S.jpg)
Please try another search
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Craig Eagle | 57 | 2021 | Independent Director |
Jeremy D. Walston | - | - | Member of Scientific Advisory Board |
Joshua N. Silverman | 54 | 2018 | Independent Chairman of the Board |
Christopher C. Chapman | 71 | 2020 | Director |
Mitchell Glass | 72 | 2024 | President, Chief Medical Officer & Director |
Christopher C. Schreiber | 59 | 2017 | Director |
Billy Joe White | 63 | 2017 | Independent Director |
Jude C. Uzonwanne | 50 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review